Late Breaking Abstract - Impact of eosinophil levels on lung function and exacerbation benefits with co-suspension delivery technology budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) in COPD (KRONOS study subgroup analysis)
Sign Up to like & getrecommendations! Published in 2018 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2018.pa688
Abstract: Objective: To assess the relationship of baseline eosinophil (EOS) levels with treatment responses to BGF MDI 320/14.4/10 µg (ICS/LAMA/LABA), glycopyrronium/formoterol [GFF] MDI 14.4/10 µg (LAMA/LABA) and budesonide/formoterol [BFF] MDI 320/10 µg (ICS/LABA). Methods: Pre-specified analysis… read more here.
Keywords: formoterol; gff mdi; bgf mdi; mdi ... See more keywords
Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS
Sign Up to like & getrecommendations! Published in 2020 at "European Respiratory Journal"
DOI: 10.1183/13993003.congress-2020.5230
Abstract: Background: In the Phase III, 52-week ETHOS study (NCT02465567), budesonide/glycopyrronium/formoterol metered dose inhaler (BGF MDI) fixed-dose combination significantly reduced exacerbations vs dual therapies. However, use of inhaled corticosteroids (ICS) may also increase pneumonia risk. Objective:… read more here.
Keywords: bgf mdi; mdi; exacerbation; pneumonia risk ... See more keywords